![]() | Alan Wayne PartinThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, 21287, United States | The James Buchanan Brady Urological Institute, Johns Hopkins ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Alan Wayne Partin:Expert Impact
Concepts for whichAlan Wayne Partinhas direct influence:Prostate cancer,Radical prostatectomy,Specific antigen,Gleason score,Biochemical recurrence,Prostate specific,Pathological stage,Clinical stage.
Alan Wayne Partin:KOL impact
Concepts related to the work of other authors for whichfor which Alan Wayne Partin has influence:Prostate cancer,Specific antigen,Biochemical recurrence,Active surveillance,Gleason score,Prostatic neoplasms,Androgen receptor.
KOL Resume for Alan Wayne Partin
Year | |
---|---|
2021 | The Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, 21287, United States Johns Hopkins Hospital, Baltimore, MD, USA |
2020 | The Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA. Department of Urology, Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland. |
2019 | Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA The Brady Urological Institute, The Johns Hopkins University , Baltimore , Maryland. |
2018 | James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA |
2017 | Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD |
2016 | The James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD 21287, USA Department of Urology, Northwestern University Feinberg School of Medicine (RSM, EMS), Chicago, Illinois James Buchanan Brady Urological Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland BALTIMORE, MARYLAND. |
2015 | James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, MD, USA Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland The Johns Hopkins Hosp, Baltimore, MD |
2014 | Johns Hopkins Hospital, Baltimore, Maryland Sungkyunkwan University Samsung Medical Center (BCJ), Seoul, South Korea Duke University Medical Center, Durham, North Carolina (SJF) |
2013 | All authors: Johns Hopkins University, Baltimore, MD. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Concept | World rank |
---|---|
biopsies 1 cancer | #1 |
evidence bcr | #1 |
nj299 | #1 |
25 psa levels | #1 |
prostate cells blood | #1 |
scan ppv | #1 |
metastases mfs | #1 |
edalnetr | #1 |
tpsad cpsad | #1 |
early diagnosis pca | #1 |
cancer range | #1 |
threshold phid | #1 |
specific prostatic neoplasms | #1 |
complexed free | #1 |
sets gels | #1 |
ct2cnos | #1 |
prias protocols patients | #1 |
• rrp lrp | #1 |
radical prostatectomy hrpc | #1 |
blood prostate cancer | #1 |
magnetic resonance psa | #1 |
biopsy pathological stage | #1 |
nomograms psa | #1 |
surgical approach plnd | #1 |
721 | #1 |
genn models | #1 |
nuclear structure response | #1 |
fpsa percent | #1 |
patients jhh | #1 |
auc acpp | #1 |
serum proteomics pattern | #1 |
gg⩾2 | #1 |
sum 7 | #1 |
calculated psa ratio | #1 |
stage gleason score | #1 |
fold psa | #1 |
90 sensitivity | #1 |
cpsa positive threshold | #1 |
long noncoding pca | #1 |
delay months | #1 |
specificity tpsa | #1 |
chiaccherini | #1 |
documented metastasis | #1 |
search jhh | #1 |
aged disease | #1 |
survival rp | #1 |
libertino | #1 |
tpsa percent | #1 |
18209 | #1 |
tpsa 90 sensitivity | #1 |
Sign-in to see all concepts, it's free! | |
Prominent publications by Alan Wayne Partin
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy
[ PUBLICATION ]
OBJECTIVES: To determine the clinical significance of Gleason score 3+4 versus 4+3 on radical prostatectomy.
METHODS: Of 2390 men who underwent radical prostatectomy by a single surgeon, 570 had Gleason score 7 tumors without lymph node metastasis, seminal vesicle invasion, or tertiary Gleason pattern 5. Patients were evaluated for biochemical recurrence (prostate-specific antigen progression) and distant metastases.
RESULTS: Eighty percent of patients had Gleason score 3+4, 20% had 4+3. ...
Known for Gleason Score | Radical Prostatectomy | 3 4 | Prognostic Significance | 7 Tumors |
CONTEXT: Biochemical disease recurrence after radical prostatectomy often prompts salvage radiotherapy, but no studies to date have had sufficient numbers of patients or follow-up to determine whether radiotherapy improves survival, and if so, the subgroup of men most likely to benefit.
OBJECTIVES: To quantify the relative improvement in prostate cancer-specific survival of salvage radiotherapy vs no therapy after biochemical recurrence following prostatectomy, and to identify subgroups ...
Known for Salvage Radiotherapy | Specific Survival | Prostate Cancer | Biochemical Recurrence | Hormonal Therapy |
PURPOSE: This study evaluated the [-2]proenzyme prostate specific antigen serum marker using a blinded reference specimen set from 3 National Cancer Institute Early Detection Research Network centers from men with an indication for prostate biopsy.
MATERIALS AND METHODS: Serum was collected before biopsy from 123 men with no prior biopsy or prostate cancer history. Specimens (cancer cases 51%, noncancer controls 49%) were selected equally from the 3 sites, and analyzed for prostate ...
Known for Specific Antigen | Prostate Cancer Detection | Cancer Institute | Curve Biomarkers | Validation Study |
CONTEXT: The percentage of free prostate-specific antigen (PSA) in serum has been shown to enhance the specificity of PSA testing for prostate cancer detection, but earlier studies provided only preliminary cutoffs for clinical use.
OBJECTIVE: To develop risk assessment guidelines and a cutoff value for defining abnormal percentage of free PSA in a population of men to whom the test would be applied.
DESIGN: Prospective blinded study using the Tandem PSA and free PSA assays (Hybritech ...
Known for Prostate Cancer | Percentage Free Psa | Benign Prostatic Disease | Specific Antigen | Unnecessary Biopsies |
PURPOSE: There have been only a few contradictory publications assessing whether Gleason score 4 + 3 = 7 has a worse prognosis than 3 + 4 = 7 on biopsy material in predicting pathological stage and biochemical recurrence. Older studies predated the use of the modified Gleason grading system established in 2005.
MATERIALS AND METHODS: We retrospectively studied 1,791 cases of Gleason score 7 on prostatic biopsy to determine whether the breakdown of Gleason score 7 into 3 + 4 vs 4 + 3 has ...
Known for Gleason Score | Radical Prostatectomy | Needle Biopsy | 7 Prostate | Primary Pattern |
PURPOSE: We addressed whether Gleason score 3 + 4 = 7 and 4 + 3 = 7 cancers on needle biopsy behave differently and whether this behavior is independent of the number of cores involved by cancer. If it is not an independent predictor of prognosis, one may report Gleason score 7 cancer with the number of positive cores without regard to whether the primary pattern was 3 or 4. This practice would remove a source of poor interobserver reproducibility when grading prostate cancer on needle ...
Known for Needle Biopsy | 3 4 | Gleason Scores | Score 7 | Prostate Cancer |
18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer
[ PUBLICATION ]
We previously demonstrated the ability to detect metastatic prostate cancer using N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC), a low-molecular-weight radiotracer that targets the prostate-specific membrane antigen (PSMA). PSMA has been shown to be associated with higher Gleason grade and more aggressive disease. An imaging biomarker able to detect clinically significant high-grade primary prostate cancer reliably would address an unmet clinical ...
Known for Dcfbc Pet | Prostate Cancer | Surface Biomarkers | Imaging 18f | Unmet Clinical |
WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: The Gleason scoring system is a well-established predictor of pathological stage and oncological outcomes for men with prostate cancer. Modifications throughout the last few decades - most recently by the International Society of Urological Pathology (ISUP) in 2005 - have attempted to improve the correlation between biopsy and radical prostatectomy Gleason sum and better stratify patients to predict clinical outcomes. Based on ...
Known for Gleason Grade | International Society | Positive Cores | Radical Prostatectomy Rp | Urological Pathology |
PURPOSE: Prostate specific antigen and free prostate specific antigen have limited specificity to detect clinically significant, curable prostate cancer, leading to unnecessary biopsy, and detection and treatment of some indolent tumors. Specificity to detect clinically significant prostate cancer may be improved by [-2]pro-prostate specific antigen. We evaluated [-2]pro-prostate specific antigen, free prostate specific antigen and prostate specific antigen using the formula, ...
Known for Prostate Specific | Multicenter Study | Biopsy Auc | Cancer Detection | Curve Biomarkers |
PURPOSE: Since 2010 pathologists at our institution have routinely been documenting the Gleason score at the margin and length of the positive surgical margin after prostatectomy. In this study we evaluate how the Gleason score and positive surgical margin length correlate with the grade and adverse pathological characteristics of the final specimen, and whether the positive surgical margin Gleason score affects the risk of early biochemical recurrence.
MATERIALS AND METHODS: A total of ...
Known for Gleason Score | Positive Surgical Margin | Radical Prostatectomy | Biochemical Recurrence | Aged Neoplasm |
PURPOSE: Percent free prostate specific antigen (PSA) is useful to select patients for prostate biopsy with total PSA 4 to 10 ng./ml. However, 20% of men with PSA between 2.6 and 4 ng./ml. harbor significant prostate cancer and percent free PSA has been suggested to aid in the decision to biopsy in this total PSA range as well. Concerns exist that the number of biopsies needed to detect 1 cancer in this range may be inappropriately high. In a prospective referral population we evaluated ...
Known for Prostate Cancer | Percent Free | Specific Antigen | Psa Range | Gleason Score |
PURPOSE: Hypermethylation of the CpG island at the promoter region of the pi-class glutathione S-transferase gene (GSTP1) is the most common somatic genome abnormality in human prostate cancer. We evaluated circulating cell-free DNA GSTP1 CpG island hypermethylation as a prognostic biomarker in the serum of men with prostate cancer.
EXPERIMENTAL DESIGN: Prostate cancer DNA GSTP1 CpG island hypermethylation was detected using a restriction endonuclease quantitative PCR technique. We ...
Known for Radical Prostatectomy | Serum Dna | Cpg Island | Specific Antigen | Psa Recurrence |
PURPOSE: Determining serum total prostate specific antigen (PSA) has proved to be a valuable diagnostic aid for detecting prostatic carcinoma, although the lack of specificity has limited its usefulness. Studies indicate that the use of percent free PSA would improve specificity while maintaining sensitivity. Since complexed PSA represents the major proportion of measurable PSA in serum, we determined whether it represents a single test alternative to the use of percent free PSA for the ...
Known for Complexed Prostate | Total Psa | Specific Antigen | Percent Free | Early Detection |
OBJECTIVES: To examine the relationship among needle biopsy primary grade, prostatectomy grade, and postprostatectomy biochemical recurrence among men with Gleason score 7 disease.
METHODS: We identified 320 men with Gleason score 7 tumors on prostate biopsy treated with radical prostatectomy between 1991 and 2001 by a single surgeon. None of these patients had received neoadjuvant or adjuvant hormonal therapy or radiotherapy. The chi-square test and Kaplan-Meier method were used to ...
Known for Gleason Pattern | Needle Biopsy | Radical Prostatectomy | Score 7 | Biochemical Recurrence |